Mattias Carlsten

List of Publications by Year
in descending order

54 papers	2,962 citations	218381 26 h-index	189595 50 g-index
55 all docs	55 docs citations	55 times ranked	4301 citing authors

#	Article	IF	Citations
1	Natural killer cell-mediated immunosurveillance of human cancer. Seminars in Immunology, 2017, 31, 20-29.	2.7	240
2	Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells. Journal of Immunology, 2009, 183, 4921-4930.	0.4	227
3	Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nature Reviews Drug Discovery, 2015, 14, 487-498.	21.5	203
4	DNAX Accessory Molecule-1 Mediated Recognition of Freshly Isolated Ovarian Carcinoma by Resting Natural Killer Cells. Cancer Research, 2007, 67, 1317-1325.	0.4	198
5	Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications. Frontiers in Immunology, 2015, 6, 266.	2.2	184
6	Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma. Clinical Cancer Research, 2016, 22, 5211-5222.	3.2	137
7	Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML. Clinical Cancer Research, 2018, 24, 1834-1844.	3.2	136
8	IFN-Î³ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. Journal of Clinical Investigation, 2002, 110, 1515-1523.	3.9	135
9	A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica, 2014, 99, e81-e83.	1.7	112
10	Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. Molecular Therapy, 2014, 22, 1388-1395.	3.7	106
11	Estimation of the Size of the Alloreactive NK Cell Repertoire: Studies in Individuals Homozygous for the Group A KIR Haplotype. Journal of Immunology, 2008, 181, 6010-6019.	0.4	99
12	Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells. Frontiers in Immunology, 2019, 10, 2357.	2.2	99
13	Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19. Frontiers in Immunology, 2016, 7, 105.	2.2	90
14	Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome. Leukemia, 2010, 24, 1607-1616.	3.3	85
15	Coordinated Expression of DNAM-1 and LFA-1 in Educated NK Cells. Journal of Immunology, 2015, 194, 4518-4527.	0.4	81
16	The Core Promoter of Human Thioredoxin Reductase 1. Journal of Biological Chemistry, 2001, 276, 30542-30551.	1.6	79
17	Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer. Frontiers in Immunology, 2019, 10, 1047.	2.2	77
18	IFN-Î³ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. Journal of Clinical Investigation, 2002, 110, 1515-1523.	3.9	75

#	Article	IF	Citations
19	NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunology, Immunotherapy, 2008, 57, 1541-1552.	2.0	74
20	Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific Immunity. Cancer Research, 2006, 66, 6387-6394.	0.4	58
21	Doxorubicin sensitizes human tumor cells to NK cellâ€•and Tâ€•cellâ€•mediated killing by augmented TRAIL receptor signaling. International Journal of Cancer, 2013, 133, 1643-1652.	2.3	54
22	Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4R334X. Frontiers in Immunology, 2019, 10, 1262.	2.2	47
23	Selenite Induces Posttranscriptional Blockade of HLA-E Expression and Sensitizes Tumor Cells to CD94/NKG2A-Positive NK Cells. Journal of Immunology, 2011, 187, 3546-3554.	0.4	40
24	Optimizing Lentiviral Transduction of Human Natural Killer Cells. Blood, 2011, 118, 4714-4714.	0.6	37
25	Natural killer cellâ€•mediated lysis of freshly isolated human tumor cells. International Journal of Cancer, 2009, 124, 757-762.	2.3	35
26	Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy. Frontiers in Immunology, 2020, 11, 621225.	2.2	34
27	Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cellâ€“mediated tumor responses. Blood Advances, 2022, 6, 3352-3366.	2.5	30
28	Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5. OncoImmunology, 2019, 8, e1534664.	2.1	25
29	Regulation of interleukin-4 signaling by extracellular reduction of intramolecular disulfides. Biochemical and Biophysical Research Communications, 2009, 390, 1272-1277.	1.0	24
30	Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness. Frontiers in Immunology, 2019, 10, 2164.	2.2	23
31	mRNA Transfection to Improve NK Cell Homing to Tumors. Methods in Molecular Biology, 2016, 1441, 231-240.	0.4	16
32	The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994â€“2016. Experimental Hematology and Oncology, 2019, 8, 7.	2.0	14
33	CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy. Methods in Molecular Biology, 2020, 2121, 213-239.	0.4	13
34	Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of follow-up. PLoS ONE, 2018, 13, e0202651.	1.1	11
35	Treatment of Ex Vivo Expanded NK Cells with Daratumumab F(ab')2 Fragments Protects Adoptively Transferred NK Cells from Daratumumab-Mediated Killing and Augments Daratumumab-Induced Antibody Dependent Cellular Toxicity (ADCC) of Myeloma. Blood, 2015, 126, 4244-4244.	0.6	10
36	Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome. British Journal of Haematology, 2021, 193, 951-960.	1.2	8

#	Article	IF	Citations
37	LIRâ€1 educates expanded human NK cells and defines a unique antitumor NK cell subset with potent antibodyâ€dependent cellular cytotoxicity. Clinical and Translational Immunology, 2021, 10, e1346.	1.7	8
38	Clinical-Grade mRNA Electroporation of NK Cells: A Novel and Highly Efficient Method to Genetically Reprogram Human NK Cells for Cancer Immunotherapy. Blood, 2014, 124, 2153-2153.	0.6	7
39	The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome. BMC Cancer, 2021, 21, 500.	1.1	5
40	A Suppressive Microenvironment in Acute Myeloid Leukemia Induces Global Alteration of T and NK Cell Profiles - Evidence for Immune-Editing Effect By Leukemia. Blood, 2014, 124, 1047-1047.	0.6	5
41	A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells <i>in vitro</i> and <i>in vivo</i>. Haematologica, 2022, 107, 1786-1795.	1.7	5
42	Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications. Molecular Imaging and Biology, 2021, 23, 952-962.	1.3	4
43	A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity. Blood, 2011, 118, 1001-1001.	0.6	3
44	Ultra-Low Dose IL-2 Safely Expands Regulatory T Cells and CD56bright NK Cells in Healthy Volunteers: Towards Safer Stem Cell Donors?. Blood, 2012, 120, 3283-3283.	0.6	2
45	Early biomarkers of response to carfilzomib in multiple myeloma (MM): Modulation of CXCR4 and induction of autophagy.. Journal of Clinical Oncology, 2014, 32, e19572-e19572.	0.8	2
46	A Phase II Trial of IPH2101 (anti-KIR mAb) in Smoldering Multiple Myeloma. Blood, 2011, 118, 2944-2944.	0.6	1
47	A Naive NK Cell Repertoire in the Circulation of Haploidentical Stem Cell Donors Pre Mobilization Predicts Rejection of Cord Myeloid Cells in Patients Undergoing Combined Haploidentical and Unrelated Cord Blood HSCT. Blood, 2016, 128, 2199-2199.	0.6	1
48	Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor. Blood, 2019, 134, 138-138.	0.6	1
49	Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 655-666.	1.4	1
50	A Novel CD34-Specific T-Cell Engager Efficiently Depletes Stem Cells and Acute Myeloid Leukemia Cells in Vitro and In Vivo. Blood, 2021, 138, 2861-2861.	0.6	1
51	Early and Transient Microchimerism Associated with Complete Remission after Adoptively Transferred Haploidentical NK Cells Against High Risk Myelodysplastic Syndrome and Refractory Acute Myeloid Leukemia. Blood, 2014, 124, 1120-1120.	0.6	0
52	mRNA Transfection of NK Cells with Gain-of-Function CXCR4 As a Novel Method to Enhance the Homing of Adoptively Transferred NK Cells to the Bone Marrow for the Treatment of Hematological Malignancies. Blood, 2015, 126, 3089-3089.	0.6	0
53	ER-Stress-Induced Suppression of HLA-E on Bortezomib-Evading Malignant Plasma Cells Dramatically Enhances Their Susceptibility to NK Cell Killing: Identification of an Achilles Heel in Myeloma Cells That Can be Utilized to Prevent Disease Relapse Following Bortezomib Treatment. Blood, 2015, 126, 4296-4296.	0.6	0
54	Ex Vivo Expanded NK Cells Mediate Highly Efficient and Rapid Killing of Ewing Sarcoma Cells Through Degranulation with Tumor Cytotoxicity Controlled by the NKG2D, DNAM-1, and NKp30 NK Receptors. Blood, 2015, 126, 1894-1894.	0.6	0